gemcitabine + paclitaxel + bevacizumab
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Breast Cancer
Conditions
Breast Cancer
Trial Timeline
May 1, 2006 → Aug 1, 2012
NCT ID
NCT00320541About gemcitabine + paclitaxel + bevacizumab
gemcitabine + paclitaxel + bevacizumab is a phase 2 stage product being developed by Eli Lilly for Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00320541. Target conditions include Breast Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00320541 | Phase 2 | Completed |
| NCT00403130 | Phase 2 | Completed |
Competing Products
20 competing products in Breast Cancer